HIGHLAND-EUROPE
7.12.2020 13:33:03 CET | Business Wire | Press release
Highland Europe has strengthened its industry-renowned team with the promotion of Jean Tardy-Joubert, Gajan Rajanathan and Ronan Shally to Partner. Tardy-Joubert and Rajanathan joined Highland in 2017/18 from Qatalyst, the San Francisco-based boutique investment bank serving the global tech sector, while Shally has been with the firm since 2014 and is Highland’s Chief Financial Officer. By promoting Gajan, Jean and Ronan, Highland Europe is better positioned than ever to help the founders it backs to achieve their ambitions. Highland Europe is differentiated by a high-touch, collaborative approach to helping companies scale globally.
Highland Europe also announces today that it closed its fourth fund, raising €700M to double-down on its strategy of backing the continent’s most outstanding founder-led teams in software and internet businesses.
Building on a track record of investing in consumer tech brands and software companies such as AMCS, Brandwatch, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, MatchesFashion, Nexthink, PhotoBox, WeTransfer, Zwift and Wolt, the new fund takes Highland Europe’s assets under management to €1.8bn.
Over the past 12 months, the firm has backed seven exceptional founding teams investing nearly €200M in Alkemics, Cobalt, DominoDatalab, Farewill, Meditopia, Modulr and Supermetrics as well as the existing portfolio. Highland Europe’s portfolio companies attracted exceptional external investment appetite with €730M follow-on investment in the last 12 months, some of which fueled seven M&A transactions completed by portfolio companies. Last but not least, the team helped two founder-led teams (Spot and Smartly.io) navigate strategic and private equity interest, resulting in substantial liquidity events.
Just as mission-critical tech and innovation have been instrumental in enabling businesses and individuals to continue functioning during the pandemic, technology looks set to play a key role in an eventual economic recovery. Reflecting this, Highland saw significant commitment from investors, resulting in an oversubscribed €700M fund.
Fergal Mullen, co-founder and partner at Highland Europe, said: “During 2020 we have seen 10-year trends in tech adoption compressed into one year across both consumer and business segments. Software has gone mainstream and it is mission-critical. The opportunity at the growth stage in Europe has never been more evident or more urgent. Highland Europe’s role is to bring capital, our deep network and scaling expertise to companies that can make it all the way to IPO. We have the track record, the team and a highly selective and focused strategy to help Europe’s most promising tech businesses become global leaders.”
‘Growth funding deficit’
Scaling software businesses to become global leaders requires expertise, insight and capital. Europe’s tech companies are proliferating at Seed and Series A, but remain starved of funding at growth stage. Figures from Dealroom.co show that European companies raised 38% of global venture capital at Seed, but this figure dropped to 21% at Series B and 14% at Series C (rounds of €40-100M). Until this is fixed, Europe will not reach its full potential, let alone challenge the dominance of the American and Asian tech giants.
Without good European sources of capital, many promising tech companies will struggle to raise the funds needed to fuel international success. According to one estimate, just one in eight European companies reach scale, compared with one in four in America. Highland Europe is determined to address this massive opportunity with a continued focus on mission-critical growth stage software and consumer technology companies, which have demonstrated compelling market traction and global ambition.
--ENDS--
About Highland Europe
Highland Europe invests in exceptional growth-stage software and internet companies. Active in Europe since 2003 as Highland Capital Partners and formally launched in 2012, Highland Europe has raised over €1.8 billion and has invested in companies such as Adjust, AMCS, Camunda, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, Malwarebytes, MatchesFashion, NewVoiceMedia, Nexthink, Spot, Supermetrics, WeTransfer, Wolt and Zwift. Highland’s collective history of investments across the US, Europe and China includes 46 IPOs and 19 billion-dollar-plus companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
